Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $1.34 by 112.69 percent. This is a 72.73 percent increase over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $959.000 million which beat the analyst consensus estimate of $883.259 million by 8.58 percent. This is a 39.49 percent increase over sales of $687.500 million the same period last year.